An observational study in Acne Vulgaris, sponsored by Sienna Labs. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-04.
Sponsored by Sienna Labs · Observational
This study evaluates the safety, effectiveness, and maintenance of effect of a novel topical silver particle solution (Sienna 755.1100, 810.1100, or 1064.1100) used in conjunction with a laser for the treatment of Acne Vulgaris.
730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.
This study's enrollment of 76 is below the median of 90 across 81 observational studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →This is the only study on the registry with Sienna Labs as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Up to 165 subjects will be considered for entry into the study. Subjects completing a predecessor facial acne study (755.1100_FA, 810.1100_FA, or 1064.1100_FA) who meet all study inclusion/exclusion criteria will be offered study participation. There will be no treatments administered in this study.
Exclusion Criteria:
Change in Total lesion count by blinded investigator
Maintenance of effect by comparing lesion counts conducted at the exit visit of the predecessor study (ie, 12 weeks post-final treatment) and visit 2 of this study (ie, 18 weeks post-final treatment).
Time frame: 18 weeks post final treatment
Change in Total lesion count by blinded investigator
Maintenance of effect by comparing lesion counts conducted at the exit visit of the predecessor study (ie, 12 weeks post-final treatment) and visit 3 of this study (ie, 24 weeks post-final treatment).
Time frame: 24 weeks post final treatment
Safety as assessed by number of adverse events
Adverse events will be monitored throughout the study
Time frame: up to 24 weeks post final treatment
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.